Related Experiment Video
Updated: Dec 17, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)
Hao Chen1, Gang Yang2, Jianchun Xiao2
1Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; School of Medicine, Tsinghua University, 1 Tsinghua Yuan Haidian District, Beijing, 100084, China.
Abstract:
Neoantigens generated in neoplasms are a type of protein completely absent in healthy tissues. Therefore, anti-tumor immunity targeting neoantigens is highly specific, which provides an optional approach to boost tumor immunotherapy. Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies in humans, with few efficient treatments to improve its prognosis. Therefore, immunotherapies reinforced by neoantigen-based strategies should be considered. In PDAC, the mutational burden is intermediate compared with other common malignancies, while the naturally formed tumor immunity is significantly inferior. Moreover, the high mutation load in PDAC correlates with a poor clinical prognosis, although the combination of a large mutation repertoire and competent T cell population is indispensable for long-term survival. In clinical practice, three strategies have been mainly used: peptide or tumor cell vaccines, neo-epitope-coding nucleotide vaccines, and dendritic cell vaccines. However, three major problems remain to be addressed, including (1) highly personalized protocols after sampling, (2) insufficient neoantigen quantity, and (3) ineffective immunotherapy of PDAC. In summary, neoantigen-based therapy of PDAC is increasing and the treatment methods are accompanied by great challenges. Currently, extensive development is needed for effective neoantigen-based therapy.
Insights
Neoantigen-based immunotherapy shows promise for pancreatic cancer (PDAC) by targeting unique tumor proteins. However, challenges in personalization, neoantigen quantity, and treatment efficacy require further research for successful clinical application.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Neoantigens, proteins absent in healthy tissue, offer specific targets for anti-tumor immunity.
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited treatment options and poor prognosis.
- PDAC exhibits intermediate mutational burden but significantly inferior natural anti-tumor immunity.
Purpose of the Study:
- To explore the potential of neoantigen-based strategies to enhance immunotherapy for pancreatic ductal adenocarcinoma (PDAC).
- To identify the challenges and future directions for effective neoantigen-based therapy in PDAC.
Main Methods:
- Review of current neoantigen-based immunotherapy strategies for PDAC, including peptide, nucleotide, and dendritic cell vaccines.
- Analysis of PDAC's mutational landscape and its impact on tumor immunity.
- Identification of key challenges hindering clinical application.
Main Results:
- Neoantigen-targeted immunotherapy presents a specific approach to boost anti-tumor immunity in PDAC.
- High mutation load in PDAC correlates with poor prognosis, yet is essential for T cell-mediated survival.
- Current clinical strategies face hurdles including personalization, neoantigen quantity, and overall treatment effectiveness.
Conclusions:
- Neoantigen-based therapy for PDAC is an emerging field with significant therapeutic potential.
- Addressing challenges in personalized protocols, neoantigen generation, and immunotherapy efficacy is crucial.
- Extensive research and development are necessary to establish effective neoantigen-based treatments for PDAC.
